Truist Lowers its Price Target on Insulet Corporation (PODD) to $360 and Maintains a Buy Rating

Insulet Corporation (NASDAQ:PODD) is among the 10 High Growth S&P 500 Stocks to Buy Now. Truist Lowers its Price Target on Insulet Corporation (PODD) to $360 and Maintains a Buy Rating Truist on February 19, 2026, lowered its price target on Insulet Corporation (NASDAQ:PODD) to $360 from $390 and maintained a Buy rating. The firm said Insulet delivered another strong Q4 beat, supported by broad global strength in Omnipod 5 as the company builds on its first-mover advantage in Type 2 diabetes and leverage ...